PremiumRatings10x Genomics: Buy Rating Reiterated on Strong 2Q26 Results and Raised 2026 Outlook; $50 Price Target Maintained2d agoTXG
10x Genomics: Buy Rating Reiterated on Strong 2Q26 Results and Raised 2026 Outlook; $50 Price Target Maintained
PremiumBlurbsAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX)2d agoTFXTXG
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX)
PremiumBlurbsAnalysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and 10x Genomics (TXG)2d agoTXGVRCA
Analysts Offer Insights on Healthcare Companies: Verrica Pharmaceuticals (VRCA) and 10x Genomics (TXG)